Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period

OBJECTIVE: Tanezumab, a nerve growth factor inhibitor, was investigated for osteoarthritis (OA) of the hip or knee in a study with 24-week treatment and 24-week safety follow-up. METHODS: This double-blind, randomised, phase III study enrolled adults in Europe and Japan with moderate-to-severe OA wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Berenbaum, Francis, Blanco, Francisco J, Guermazi, Ali, Miki, Kenji, Yamabe, Takaharu, Viktrup, Lars, Junor, Rod, Carey, William, Brown, Mark T, West, Christine R, Verburg, Kenneth M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Osteoarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286052/
https://www.ncbi.nlm.nih.gov/pubmed/32234715
http://dx.doi.org/10.1136/annrheumdis-2019-216296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286052/
https://www.ncbi.nlm.nih.gov/pubmed/32234715
http://dx.doi.org/10.1136/annrheumdis-2019-216296

Ejemplares similares